Thus, FOXP3-expression and the associated regulatory phenotype might be an adverse biologic and clinical factor in rare PTCL cases that contributes to the aggressiveness of the tumor. Here, FOXP3 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.